false
0001757499
0001757499
2026-09-09
2026-09-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of report (date of earliest event reported): September 9, 2026
SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-41488 |
|
82-5089826 |
(State
or other jurisdiction
of
incorporation) |
|
Commission
File
Number |
|
(IRS
Employer
Identification
No.) |
401
Professional Drive, Suite 260
Gaithersburg,
MD 20879
(Address
of principal executive offices) (Zip Code)
(240)
430-4212
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR |
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| Common
Stock $0.00001 per share |
|
SHPH |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
September 9, 2026, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Meeting”).
As
of August 6, 2026, the record date for the Meeting, 1,027,214 shares of the Company’s common stock, par value $0.00001 per share
(“Common Stock”), were issued and outstanding, with each share entitled to one vote on each proposal at the Meeting. At the
Meeting, the stockholders holding an aggregate of 588,987 shares of Common Stock entitled to vote at the Meeting were represented in
person or by proxy, representing approximately 57.33% of the outstanding shares of Common Stock, and thereby a quorum was present for
the Meeting.
The
final results for each of the proposals considered at the Meeting are set forth below, as certified by the inspector of elections for
the Meeting. These proposals are described in further detail in the Definitive Proxy Statement on Schedule 14A filed by the Company with
the U.S. Securities and Exchange Commission on August 13, 2026, as supplemented (the “Proxy Statement”).
Proposal
No. 1: To approve, for purposes of Nasdaq Listing Rule 5635, the issuance of (a) up to approximately 3,389,337 shares of Shuttle Common
Stock in connection with the conversion of shares of Series B-1 Preferred Stock issued pursuant to the transactions contemplated by the
Merger Agreement dated April 30, 2026 with United Dogecoin Inc. and described further in the Proxy Statement, (b) pre-funded warrants
and up to approximately 12,292,752 shares of Shuttle Common Stock in connection with the exercise of such pre-funded warrants pursuant
to the transactions contemplated by the Merger Agreement, (c) up to approximately 108,905 shares of Shuttle Common Stock in connection
with the conversion of shares of Series B-1 Preferred Stock issued pursuant to the transactions contemplated by the Second Amendment
to Asset Purchase Agreement as described further in the Proxy Statement, (d) pre-funded warrants and up to approximately 384,431 shares
of Shuttle Common Stock in connection with the exercise of such pre-funded warrants pursuant to the transactions contemplated by the
Second Amendment, (e) up to approximately 302,475 shares of Shuttle Common Stock in connection with the conversion of 750 shares of Series
B-1 Preferred Stock issued and paid to E.F. Hutton & Co. as a financial advisory fee pursuant to the transactions contemplated by
the Merger Agreement, and (f) pre-funded warrants and up to approximately 1,106,611 shares of Shuttle Common Stock in connection with
the exercise of such pre-funded warrants to E.F. Hutton & Co. as a financial advisory fee pursuant to the transactions contemplated
by the Merger Agreement.
| For |
|
Against |
|
Abstentions |
|
Broker
Non-Votes |
| 442,624 |
|
11,145 |
|
26 |
|
135,192 |
A
majority of the shares present in person or by proxy and entitled to vote at the Meeting was required to approve Proposal No. 1 as provided
above (“Proposal No. 1”). Accordingly, Proposal No. 1 was approved.
Proposal
No. 2: To approve, for purposes of Nasdaq Listing Rule 5635, the issuance of (a) up to approximately 927,114 shares of Shuttle Common
Stock in connection with the conversion of shares of Series B-2 Preferred Stock issued pursuant to the transactions contemplated by the
Securities Purchase Agreement dated April 30, 2026 and described further in the Proxy Statement, (b) up to approximately 927,114 shares
of Shuttle Common Stock in connection with the exercise of common stock purchase warrants issued pursuant to the transactions contemplated
by the Securities Purchase Agreement and (c) pre-funded warrants and up to approximately 3,148,619 shares of Shuttle Common Stock in
connection with the exercise of such pre-funded warrants pursuant to the transactions contemplated by the Securities Purchase Agreement.
| For |
|
Against |
|
Abstentions |
|
Broker
Non-Votes |
| 442,193 |
|
11,579 |
|
23 |
|
135,192 |
A
majority of the shares present in person or by proxy and entitled to vote at the Meeting was required to approve Proposal No. 2 as provided
above (“Proposal No. 2”). Accordingly, Proposal No. 2 was approved.
Proposal
No. 3: To approve an amendment to the Company’s 2018 Equity Incentive Plan to increase the number of shares of Common Stock authorized
for issuance thereunder to 8,800,000.
| For |
|
Against |
|
Abstentions |
|
Broker
Non-Votes |
| 428,743 |
|
25,023 |
|
29 |
|
135,192 |
A
majority of the shares present in person or by proxy and entitled to vote at the Meeting was required to approve Proposal No. 3 as provided
above (“Proposal No. 3”). Accordingly, Proposal No. 3 was approved.
Proposal
No. 4: To approve an amendment to the Company’s Certificate of Incorporation to change the name of the Company to United Compute
Inc.
| For |
|
Against |
|
Abstentions |
|
Broker
Non-Votes |
| 576,928 |
|
10,868 |
|
1,191 |
|
- |
A
majority of the outstanding shares of Common Stock was required to approve Proposal No. 4 as provided above (“Proposal No. 4”).
Accordingly, Proposal No. 4 was approved.
Proposal
No. 5: Approval of Adjournment of the Meeting
| For |
|
Against |
|
Abstentions |
|
Broker
Non-Votes |
| 574,704 |
|
14,056 |
|
227 |
|
- |
Although
the proposal to adjourn the Meeting (“Proposal No. 5”) was deemed not necessary because there was a quorum present and there
were sufficient votes at the time of the Meeting to approve all other proposals, a majority of shares present in person or by proxy and
entitled to vote at the Meeting approved Proposal No. 5.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit
No. |
|
Description |
| |
|
|
| 104 |
|
Cover
Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
September 11, 2026
| |
SHUTTLE
PHARMACEUTICALS HOLDINGS, INC. |
| |
|
|
|
By: |
/s/
Christopher Cooper |
| |
Name:
|
Christopher
Cooper |
| |
Title:
|
Co-Chief
Executive Officer |